Human immunodeficiency virus type 1 (HIV-1) along with simian immunodeficiency viruses from chimpanzees (SIV cpz ) and three species of Old World monkeys from the genus Cercopithecus have been shown to encode a Vpu protein. To date, the functional characterization of Vpu has been limited to a small number of subtype B and more recently subtype C Vpu proteins. Using a recently developed VpuEGFP reporter system, we have shown that the subtype B and C Vpus are capable of preventing CD4 from being expressed on the cell surface. Using the same reporter system, we report here on the expression and functional analysis of Vpu protein from four SIV cpz isolates (CAM13, ANT, TAN1, and GAB1). All four SIV Vpu fusion proteins were efficiently expressed and prevented CD4 expression on the cell surface and induced CD4 degradation. This was surprising as three of the SIV cpz Vpu fusion proteins had only one canonical casein kinase II (CK-II) site (CAM13, ANT, TAN1) while previous studies with laboratory adapted HXB2 had indicated that both CK-II sites were required for CD4 degradation. Both ANT and TAN1 Vpu sequences encoded five consecutive negatively charged amino acids residues following the only CKII site (SAIEEDEE for ANT; SGVEEDEE for TAN1). We thus explored the possibility that this stretch of negatively charged amino acids might substitute for the lack of second CK-II site. Substitution of the aspartic acid at position 61 and glutamic acid at position 63 in the SIV cpz ANT Vpu within with lysine residues abolished the ability of this protein to down-modulate cell surface expression of CD4. Similarly, change of a serine to an alanine residue following the single consensus CK-II site of the CAM13 Vpu (SGNESDGGEEE) abolished CD4-down-regulation, suggesting that this serine was phosphorylated in the absence of a canonical CK-II site. Our results indicate that the serine was required, suggesting that this serine was phosphorylated by CK-II or possibly another cellular kinase. Taken together, these results show for the first time that Vpu proteins from SIV cpz isolates, although quite diverse in sequence and predicted secondary structure from the HIV-1 subtype B protein, are capable of down-regulating CD4, which is one of the major functions of the HIV-1 protein. D
Introduction
Human immunodeficiency virus type 1 (HIV-1) encodes for a small membrane bound protein Vpu, which has been shown to be encoded from the same mRNA that encodes the envelope glycoprotein precursor (Hout et al., 2004; Schwartz et al., 1990) . Studies on the Vpu protein from HIV-1 subtype B isolates have shown that Vpu is localized predominantly to the Golgi complex and has two important functions within the virus infected cell (Kimura et al., 1994; Pacyniak et al., 2005; Strebel et al., 1989) . One is the enhancement of virion release from infected cells, which has been associated with the transmembrane domain (Bour et al., 1995; Klimkait et al., 1990; Schubert et al., 1996a Schubert et al., , 1996b the Vpu protein is the down-modulation of CD4, which is believed to reside within the cytoplasmic domain of the protein (Willey et al., 1992; Vincent et al., 1993) . Both of the predicted alpha-helical domains, the transmembrane domain, and the phosphorylation of the serine residues within the casein kinase II sites of the cytoplasmic domain have been shown to be essential to the CD4 down-regulation property of Vpu (Paul and Jabbar, 1997; Tiganos et al., 1998) . In addition to cell culture studies, the Vpu protein is also a determinant of in vivo primate lentiviral pathogenicity. Using the simianhuman immunodeficiency virus (SHIV)/macaque model, we have shown that an intact Vpu contributes to the rapid loss of circulating CD4 + T cells in macaques infected with these pathogenic SHIVs (McCormick-Davis et al., 1998; Singh et al., 2001 Singh et al., , 2003 Stephens et al., 2002) .
Although the majority of the simian immunodeficiency viruses (SIV) lack a vpu gene, this gene is also encoded by SIVs naturally infecting chimpanzees (SIV cpz ), greater spotnosed monkeys (SIV gsn ), mona monkeys (SIV mon ), and mustached monkeys (SIV mus ) (Barlow et al., 2003; Courgnaud et al., 2002 Courgnaud et al., , 2003 Santiago et al., 2002) . However, the predicted amino acid sequence of the Vpu proteins from these various SIVs, including SIV cpz strains from central (Pan troglodytes troglodytes) and eastern (Pan troglodytes schweinfurthii) chimpanzees, while retaining one or more consensus casein kinase II motifs in the cytoplasmic domain, are highly divergent from each other as well as from HIV-1 group M Vpu sequences. Thus, it remains unknown whether these structural homologues of the HIV-1 Vpu have the same functions (CD4 down-modulation and enhancement of virion release).
Recently, we developed a reporter system that permits analysis of intracellular transport and CD4 down-regulation by Vpu (Pacyniak et al., 2005; Singh et al., 2003) . In this study, we have used this reporter system to analyze the intracellular transport and CD4 down-regulating function of four SIV cpz Vpu proteins. We show that despite their sequence divergence from each other as well as HIV-1 group M, N, and O isolates, these four SIV cpz Vpu proteins were capable of down-modulating cell surface expression of human CD4.
Results
Predicted secondary structure and phylogenetic analysis of HIV-1 and the SIV cpz Vpu proteins
The secondary structure of the SIV cpz Vpu proteins were compared to the well-studied subtype B Vpu protein. As shown in Fig. 1 , the subtype B and C Vpu proteins as well as all four of the SIV cpz Vpu proteins had a predicted transmembrane domain at the N-terminus of the protein. As previously reported, the cytoplasmic domain subtype B Vpu protein had a predicted secondary structure which consisted of two a-helical regions that were separated by a random coil region (Schubert and Strebel, 1994; Schubert et al., Fig. 1 . The sequence and predicted secondary structure of the Vpu proteins analyzed in this study. Sequence of the Vpu proteins analyzed with the isolate name to the left of the sequences. Those residues bolded and in italics represent the potential casein kinase II sites. The residues of the SIV cpz ANT and SIV cpz CAM13 sequences with a diamond above them correspond to residues that were altered by site-directed mutagenesis as described in the text. 1994). Two of the four SIV cpz Vpu proteins, SIV cpz GAB1, and SIV cpz CAM13, had cytoplasmic domains with a similar predicted secondary structure to the subtype B Vpu. The two other SIV cpz Vpu proteins (TAN1 and ANT) had a predicted secondary structure that was much different from the subtype B Vpu. In addition to the predicted transmembrane domain from amino acids 11 to 31, the SIV cpz TAN1 Vpu protein had one predicted a-helical region in the predicted cytoplasmic domain from amino acid residues 32 to 54, which was followed by five consecutive negatively amino acids. The SIV cpz ANT Vpu had a predicted transmembrane domain from amino acids 5 to 27 and two a-helical regions in the cytoplasmic domain from amino acids 28 to 38 and 44 to 64, which was also followed by five consecutive negatively amino acids. This is not surprising given that the SIV cpz Ptt strains are as closely related to each other as they are to HIV-1 groups M and N, whereas the SIV cpz Pts strains are highly divergent from both HIV-1 and SIV cpz Ptt strains (Fig. 2) . Thus, consistent with the phylogenetic relationships of these viruses, the Vpu proteins from SIV cpz Ptt strains (CAM13 and GAB1) had secondary structure that was similar to HIV-1 while the SIV cpz Pts strains exhibited structural features that were quite distinct.
Expression of the SIV cpz Vpu fusion proteins
We first transfected 293 cells with vectors expressing either the subtype B VpuEGFP, the subtype C Vpu SC EGFP1, EGFP or each of the four SIV cpz EGFP constructs followed by radiolabeling and immunoprecipitation of EGFP containing proteins with an antibody against EGFP. The results are shown in Fig. 3 . Using an antiserum specific for EGFP, EGFP-specific proteins were immunoprecipitated from cells transfected with pcEGFP, pcvpu SC EGFP1, and pcVpuEGFP having an M r of 26,000, 34,000, and 43,000, respectively (Pacyniak et al., 2005; Singh et al., 2003) . Immunoprecipitation of EGFP-specific proteins from 293 cells transfected with vectors expressing the four SIV cpz Vpu fusion proteins revealed that the Vpu TAN1 EGFP and Vpu ANT EGFP had an M r of approximately 43,000 while the Vpu GAB1 EGFP and Vpu CAM13 EGFP had an M r of approximately 32,000. These results indicate that despite the Vpu proteins being approximately the same length (82 to 88 amino acids), the fusion proteins with EGFP had markedly different M r by SDS-PAGE. This finding is similar to what we recently found in a recent study of subtype B and C Vpu fusion proteins (Pacyniak et al., 2005) .
The SIV cpz Vpu fusion proteins are associated with membrane-enriched fractions
We determined if the four SIV cpz VpuEGFP chimeric proteins were associated with the membrane fractions of the cell. 293 cells were transfected with vectors expressing EGFP, VpuEGFP, Vpu SC EGFP1 or the four SIV cpz VpuEGFP constructs. At 48 h, the cells were radiolabeled with 35 Smethionine/cysteine, P100 and S100 fractions isolated, and the EGFP containing proteins were immunoprecipitated from each fraction using an anti-EGFP serum. As shown in Fig. 4 , transfection of cells with the vector expressing EGFP vector resulted in the EGFP remaining in the S100 fraction (Lane 1). In contrast, transfection of cells with the vectors expressing VpuEGFP (Fig. 4 , lane 4) the Vpu SC EGFP1 (Fig. 3 , Lane 6) resulted in these proteins associated with the membraneenriched P100 fraction. Similar to 293 cells transfected with vectors expressing VpuEGFP or Vpu SC EGFP1, Vpu fusion proteins were immunoprecipitated from P100 fractions isolated from cells transfected with vectors expressing each of the four SIV cpz Vpu constructs. These results suggest that all four SIV cpz Vpu fusion proteins were associated with membrane-enriched P100 fractions. troglodytes are shown in red, while those from P. t. schweinfurthii are shown in blue; strains which gave rise to the vpu genes analyzed in this study are boxed. Concatenated Vif-Vpr-Vpu amino acid sequences (370 consensus length) of SIV cpz CAM13 (GenBank accession number AY169968), SIV cpz GAB1 (X52154), SIV cpz TAN1 (AF447763), and SIV cpz ANT (U42720) were compared to the corresponding sequences in SIV cpz US (AF103818), SIV cpz CAM3 (AF115393), SIV cpz CAM5 (AJ271369); HIV-1 group N strain YBF30 (AJ006022), group O strains ANT70 (L20587) and MVP5180 (L20571), and group M subtypes B (strain HXB2; K03455) and C (96BW16B01; AF110976). Sequences were aligned using Clustal W (Thompson) , with minor manual adjustment. Trees were estimated using the neighbor joining method (Saitou and Nei, 1987) . Numbers denote branches with bootstrap values of at least 70%. The scale bars indicate 0.2 replacements per site. Phylogenetic relationships of the vpu genes analyzed in this study.
Intracellular localization of the SIV cpz Vpu fusion proteins
We next examined the intracellular localization of the four SIV cpz Vpu fusion proteins. Consistent with previous results, transfection of vectors expressing EGFP and ECFPGolgi revealed a diffuse expression of EGFP consistent with cytoplasmic expression of this protein (Figs. 5A -D) . Co-transfection of 293 cells with vectors expressing VpuEGFP and DsRed-ER resulted in partial co-localization (Figs. 5E-H) and co-transfection with vectors expressing VpuEGFP and ECFP-Golgi resulted in a localization to the Golgi complex (Figs. 5I-L), which is similar to our previous observations (Pacyniak et al., 2005) . In contrast, co-transfection with vectors expressing Vpu SC EGFP1 and ECFP-Golgi resulted partial co-localization at an intracellular location (Figs. 5M-P) while co-transfection with vectors expressing Vpu SC EGFP1 and ECFP-Mem resulted in nearly complete co-localization, including expression at the cell plasma membrane (Figs. 5Q -T Fig. 8A , co-transfection with vectors expressing either VpuEGFP and human CD4 clearly resulted in degradation of human CD4, whereas the expression of EGFP alone did not result in CD4 degradation. Co-transfection of vectors expressing CD4 and each of the various SIV cpz Vpu fusion proteins also resulted in the S-methionine/cysteine for 5 h. Cells were then used to prepare S100 and P100 fractions as described in the text. The odd numbered lanes are immunoprecipitation reactions of EGFP proteins from S100 fractions, whereas the even-numbered lanes are immunoprecipitation reactions of EGFP proteins from membrane-enriched P100 fractions. Disruption of the negatively charged domain carboxyl terminal to the CK-II site of the SIV cpz ANT Vpu results in a fusion protein that no longer prevents CD4 expression on the cell surface
The SIV cpz ANT, CAM13, and TAN1 Vpu proteins have a single potential casein kinase II (CK-II; S/T-X-X-E/D) site (Fig. 1 ), yet previous studies on the HIV-1 subtype B Vpu protein indicate that both sites are required for CD4 downregulation (Paul and Jabbar, 1997) . Inspection of the sequence revealed that the SIV cpz TAN1 and ANT Vpu proteins have a stretch of 5 consecutive negatively charged amino acids (see Fig. 1 ) just carboxyl to the CK-II site (and where the second CK-II is located in the subtype B and C proteins). We determined whether these five consecutive negatively charged amino acids could substitute for the lack of a CK-II site. Using site-directed mutagenesis, we changed the aspartic acid residue at position 61 to asparagine [Vpu ANT EGFP(D61N)] or lysine [Vpu ANT EGFP(D61K)] residues. An additional vector was constructed in which the aspartic acid and glutamic acid residues at positions 61 and 63 were changed in ANT to positively charged lysine residues [Vpu ANT EGFP(DE61,63KK)]. Transfection of these constructs into HeLa CD4 + cells was analyzed for CD4 expression (Table 1, Fig. 9 ). The results indicate that Vpu ANT EGFP(D61N) and Vpu ANT EGFP(D61K) did not prevent CD4 expression on the cell surface and this was also true for the third mutant, Vpu ANT EGFP(DE61,63KK). In addition, we also analyzed the ability of these mutants to induce the degradation of human CD4. Co-transfection of vectors expression human CD4 and Vpu ANT EGFP(D61N) or Vpu ANT EGFP(DE61,63KK) failed to induce the degradation of human CD4 (Fig. 10) . Thus, these results indicated that an intact negatively charged region carboxyl to the single CK-II was required for the CD4 down-regulation by this SIV cpz ANT Vpu. . At 48 h, cells expressing EGFP and ECFP or EGFP and DsRed2 were identified and images were collected using laser scanning confocal microscopy as described in Materials and methods. Panels A, E, and I show EGFP containing protein expression layered onto a phase contrast micrograph of the field. Panels B, F, and J show marker protein expression layered onto a phase contrast micrograph of the field. Panels C, G, and K show EGFP and marker protein expression layered onto a phase contrast micrograph of the field. Panels D, H, and L merge fluorescent micrographs of EGFP fusion proteins and marker protein expression.
The SIV cpz CAM13 Vpu protein requires a second serine in the hinge region for CD4 down-regulation
The CAM13 Vpu protein also lacked a second consensus CK-II site, but contained a second serine following the first CK-II site. To determine if this serine was crucial to the CD4 down-regulation, we changed this serine residue to an alanine residue [Vpu CAM13 EGFP(S55A)]. Transfection of the vector expressing this protein into HeLa CD4 + cells clearly shows that this mutant did not prevent human CD4 surface expression (Fig. 11, Table 1 ). Similarly, co-transfection of 293 cells with vectors expressing CD4 and Vpu CAM13 EGFP(S55A) did not result in CD4 degradation (data not shown). Together, these results indicate that the second serine in the hinge region was required for CD4 down-regulation and degradation by the CAM13 Vpu protein.
Discussion
In this study, we have analyzed four Vpu homologues from SIV cpz for their intracellular transport properties and the ability to down-regulate CD4. While these Vpu Fig. 7 . CD4 down-modulation by EGFP, Vpu SC EGFP1, and SIV cpz VpuEGFP fusion proteins. HeLa CD4 + cells, which express CD4, were transfected with vectors expressing EGFP (Panels A -C), Vpu SC EGFP1 (Panels D -F), Vpu CAM13 EGFP (Panels G -I), or Vpu TAN1 EGFP (Panels J -L). At 48 h posttransfection, cells were stained for surface CD4 using a-CD4 antibody and a rhodamine conjugated secondary antibody followed by fixation with 1% formalin. Cells were examined by laser scanning confocal microscopy. Panels A, D, G, and J. Cells examined using a filter to visualize CD4 expression and layered onto a phase contrast image of the cell. Panels B, E, H, and K. Cells were examined using an appropriate filter to visualize identify cells expressing the EGFP or EGFP fusion proteins. Panels C, F, I, and L. Merge of fluorescent micrographs with both filters (for expression of Vpu fusion protein and CD4 expression. Panels A -C, cells transfected with a vector expressing EGFP. Panels D -F, cells transfected with a vector expressing Vpu SC EGFP1. Panels G -I, cells transfected with a vector expressing Vpu CAM13 EGFP. Panels J -L, cells transfected with a vector expressing Vpu TAN1 EGFP. Cells transfected with vectors Vpu CAM13 EGFP and Vpu ANT EGFP showed CD4 down-regulation that was similar to the Vpu GAB1 EGFP and Vpu TAN1 EGFP (data not shown).
homologues are similar in length, they differ by up to 83% in their amino acid sequence from the HXB2 Vpu protein. Additionally, three of the four SIV cpz Vpu proteins contain a single potential CK-II site (defined by the motif S/T-X-X-E/D with the serine or threonine residues phosphorylated) while this region is highly conserved in almost all Vpu proteins (McCormick-Davis et al., 2000) . Since phosphorylation of the two serine residues in the two CK-II motifs was shown to be necessary for the interaction of the HXB2 Vpu cytoplasmic domain with the CD4 molecule and is required for the CD4 degradation (Paul and Jabbar, 1997; Schubert and Strebel, 1994; Schubert et al., 1994) , we determined whether the lack of a second CK-II site would alter SIV cpz Vpu function. Using a recently developed EGFP reporter system (Pacyniak et al., 2005; Singh et al., 2003) , we found that all four SIV cpz Vpu fusion proteins mediated CD4 degradation via the proteasome and prevented cell surface expression of CD4. Unlike a previous study that reported that the subtype B Vpu protein required both consensus CK-II sites for CD4 down-regulation (Paul and Jabbar, 1997), our results indicated that the SIV cpz Vpu fusion proteins did not require two consensus CK-II sites. Nonetheless, two SIV cpz Vpu proteins containing a single consensus CK-II site (ANT and TAN1) also contained a stretch of negatively charged residues just carboxyl to the consensus CK-II site. Phosphorylation at CK-II sites can in some cases be substituted with negatively charged amino acid residues, particularly aspartic acid residues (Firzlaff et al., 1991; Hall et al., 1996) . We speculated that the negatively charged residues might be able to compensate for the lack of a second CK-II site. This was indeed the case as the introduction of uncharged or positively charged amino acids into this region abrogated CD4 down-regulation. Thus, at least for the SIV cpz ANT Vpu protein, negatively charged residues downstream of the CK-II site were sufficient for the CD4 down-regulation and degradation. This observation is consistent with sequence of other SIV Vpu proteins. For example, the predicted Vpu sequence of SIV mon has a stretch of six negatively charged amino acids following the one potential CK-II site and two Vpu sequences from SIV gsn have a stretch of five consecutive negatively charged amino acids in the region of the protein where the casein kinase II sites normally reside. Whether these Vpu proteins are capable of down-regulating cell surface CD4 has not yet been reported.
The Vpu proteins from SIV cpz strains isolated from Pan troglodytes troglodytes, CAM13 and GAB1, also downregulated CD4 expression. While the GAB1 sequence has the two consensus CKII sites that are normally found in HIV-1 Vpu proteins (McCormick-Davis et al., 2000) , the CAM13 has only one consensus CK-II site, but has a second serine residue following the first CK-II site (SGNESDGGEEEK with the CK-II site bolded). To determine if this serine was essential to CD4 downregulation, we changed this second serine residue to an alanine residue. The results demonstrated that this amino acid substitution abrogated CD4 down-regulation. It is possible that CK-II phosphorylates this serine even in the absence of the consensus recognition sequence as it is unlikely that the hydroxyl group (the difference between serine and alanine) is responsible for the CD4 downregulating activity of the this protein. Whether this occurs through the interaction with the h-TrCP protein, as has been demonstrated for subtype B Vpu protein (Margottin et al., 1998) , or an alternative mechanism, remains to be determined. However, the fact that the proteasome inhibitor MG132 prevented SIV cpz Vpu-mediated degradation, suggests a similar mechanism (Fujita et al., 1997; Schubert et al., 1998) . It is of interest that members of the SIV cpz lineages appear to achieve CD4 down-regulation by different mechanisms. Vpu proteins of SIV cpz strains from P. t. schweinfurthii (ANT and TAN1) probably utilize a negatively charged region following the single consensus CK-II, whereas the two Vpu proteins from P. t. troglodytes (CAM13 and GAB1) utilize phosphorylated serine residues.
Studies on the subtype B Vpu protein have shown that this protein is localized predominantly to the perinuclear region (RER/Golgi complex) with little if any, transported to the cell plasma membrane (Kimura et al., 1994; Klimkait et al., 1990; Schubert et al., 1996a Schubert et al., , 1996b Tiganos et al., 1998) . Using this reporter system, we showed that the subtype B Vpu fusion protein was transported to same intracellular compartments previously reported while Vpu fusion proteins generated with genes from three primary HIV-1 subtype C Vpu EGFP fusion proteins were transported to the cell plasma membrane (Pacyniak et al., 2005) . In this study, we also showed that the carboxyl terminus of the well studied HXB2 Vpu protein had a structural determinant or sequence that resulted in retention in the Golgi complex (Pacyniak et al., 2005) . Our studies here showed that all four SIV cpz fusion proteins, constructed in the same manner as the HIV-1 subtype B and C Vpu fusion proteins, were also transported to the cell plasma membrane, or a total of seven Vpu proteins that were transported to the cell plasma membrane. To date, virtually all structurefunction studies have been formed using the Vpu proteins from HXB2 and NL4-3 (which contains the vpu from the BRU isolate). As these two Vpu proteins are highly related to each other (McCormick-Davis et al., 2000) and are derived from laboratory-adapted T cell tropic HIV-1 it raises the question, ''Is the predominant intracellular localization of HXB2 an artefact of its laboratory adaptation?'' The intracellular localization of the HXB2 Vpu does not appear to be an artefact of fusion to EGFP as fusion of the HIV-1 subtype B and C Vpu proteins and the SIV cpz ANT to another fluorescent protein (HcRed1) also resulted in the same intracellular localization (unpublished observations). This could be potentially important as the other major function associated with the Vpu protein is enhanced virion release from cells. Since HIV-1 maturation in CD4 + T cells typically occurs at the cell plasma membrane and involves members of the endosomal sorting complex required for transport (ESCRT) I, II, and III complexes (MartinSerrano et al., 2003; Stuchell et al., 2004; von Schwedler et al., 2003) , studies with additional Vpu proteins from clinical isolates may provide further information on the potential interactions with these complexes.
Materials and methods
Cells and vpu genes, and subcellular marker plasmids 293 cells were used for the transfection studies to assess the intracellular localization of the fusion proteins and were maintained in Dulbecco's minimal essential medium (DMEM), supplemented with 2 mM glutamine, 5 Ag per ml gentamicin and 10% fetal bovine serum. HeLa CD4 + cells were used to assess CD4 down-modulation and were maintained in DMEM supplemented with 2 mM glutamine, 5 Ag per ml gentamicin and 10% fetal bovine serum and 1 mg/ml Geneticin (G-418). For the studies reported here, we used the vpu genes from four SIV cpz strains (ANT, CAM13, GAB1, and TAN1) (Huet et al., 1990; Nerrienet et al., 2004; Peeters et al., 1989 Peeters et al., , 1992 Santiago et al., 2003a Santiago et al., , 2003b Vanden Haesevelde et al., 1996) . The origin of the SIV cpz viruses in this study is shown in Table 2 . The CAM13, TAN1 and ANT vpu genes were amplified directly from fecal virion RNA and thus these vpu genes were derived from samples without prior passage in culture. Subcellular marker plasmids pDsRed2-ER (catalog number 632409), pECFP-Golgi (catalog number 632357) and pECFP-Mem (catalog number 632360) were obtained from Clontech (Palo Alto, Ca). The vpu genes used for the construction of the subtype B and C Vpu proteins were the HXB2 (with a corrected initiation codon) and the C-96BW16B01 isolates, respectively. Unlike the HXB2 Vpu which is derived from a T cell line adapted HIV-1 isolate, Fig. 11 . The second serine within the hinge region of the Vpu CAM13 EGFP is required for CD4 down-regulation. HeLa CD4 + cells, which express CD4, were transfected with vectors expressing Vpu CAM13 EGFP (Panels A -D) Vpu CAM13 EGFP(S55A) (Panels E -H). At 48 h post-transfection, cells were stained for surface CD4 using an anti-CD4 antibody and goat anti-mouse secondary antibody followed by fixation with 1% formalin. Cover slips were mounted and examine by confocal microscopy. Panels A and E, cells examined using a fluorescein filter to visualize EGFP expression and layered onto a phase contrast image of the field. Panels B and F, cells were examined using a rhodamine filter to identify cells expressing the cell surface CD4 and layered onto a phase contrast image of the field. Panels C and G, EGFP and rhodamine images were layered onto phase contrast images of the field. Panels D and H, fluorescent micrographs of EGFP and rhodamine images to visualize expression of Vpu fusion protein and CD4. the C-96BW16B01 vpu was amplified directly from patient PBMCs without passage in culture (Novitsky et al., 1999) . The amino acid sequence of the Vpu proteins analyzed in this study is shown in Fig. 1 .
Phylogenetic analysis
Concatenated amino acid sequences spanning the VifVpr-Vpu region (370 amino acids consensus length) of representative HIV-1 and SIV cpz strains were aligned using CLUSTAL W (Thompson et al., 1994) . Gaps in any of the sequences or ambiguous areas were excluded from all comparisons. Phylogenies were inferred by neighbor-joining method (Saitou and Nei, 1987) and subjected to bootstrap analysis with 1000 subreplicates.
The subtype B and C Vpu fusion proteins and the construction of the plasmids expressing the Vpu ANT EGFP, Vpu CAM13 EGFP, Vpu GAB1 EGFP, and Vpu TAN1 EGFP fusion proteins
The construction of vectors expressing the subtype B and subtype C Vpu proteins fused to the SC gene of enhanced green fluorescent protein (VpuEGFP and Vpu EGFP1, respectively) have been described (Pacyniak et al., 2005; Singh et al., 2003) . The expressed VpuEFGP was localized predominantly to the Golgi complex and prevented cell surface expression of CD4 (Singh et al., 2003) . The Vpu SC EGFP1 was found to be expressed at the cell surface (Pacyniak et al., 2005) . Thus, the VpuEGFP and the Vpu SC EGFP1 were used to compare the intracellular expression of the SIV cpz ANT fusion proteins. For the construction of the SIV cpz VpuEFGP chimeric proteins (Vpu ANT EGFP, Vpu CAM13 EGFP, and Vpu GAB1 EGFP, and Vpu TAN1 EGFP), a similar strategy was used consisting of: (1) amplification of the vpu gene with the restriction endonuclease NcoI sites at either end of the gene; (2) cloning the amplified product into the pGEMT-Easy vector; (3) digestion of the pGEMT-Easy vector containing the Vpu insert with NcoI and subcloning into the NcoI site of the pEGFP vector (Clontech); (4) sequencing the insert for correct orientation in the pEGFP vector; and (5) digestion of the pEGFP vector containing the fused VpuEFGP genes with KpnI and StuI and subcloning into the pcDNA3.1 (+) that was digested with KpnI and EcoRV.
Transfection and intracellular localization studies
VpuEGFP and other fusion proteins were transfected into human 293 cells to assess their subcellular localization using a cationic polymer (polyethylenimine) transfection reagent (ExGeni 500, MBI Fermentas) using the manufacturer's protocol. Briefly, 1 -3 Â 10 5 cells were seeded into each well of 6 well tissue culture plate 24 h prior to transfection. Transfection was carried out on cultures that were 50-60% confluent using 4.75 Ag plasmid DNA and 15.5 Al of ExGeni 500 corresponding to 6 equivalents. Each plasmid DNA samples and polyethylenimine were diluted in 300 Al of 150 mM sodium chloride solution separately. Samples were vortexed gently and immediately centrifuged at low speed for few seconds. Polyethylenimine was then added to the plasmid DNA solution, mixed with a vortex and allowed to stand at room temperature for 10 min. The 293 cells were washed with serum-free media twice and added with 3.0 ml of DMEM. Polyethylenimine/DNA mixture was added to the cells and the plate swirled by slow hand rotation for couple of seconds. Culture plates were centrifuged at 280 Â g for 5 min and incubated at 37 -C for 30 min. The medium from transfected cultures was replaced with fresh complete growth media and cells were incubated at 37 -C in 5% CO 2 atmosphere. For confocal microscopy, 293 cells were plated onto cover slips. To prepare cells for detection of EGFP fluorescence, the medium was removed after 48 h following transfection, the monolayers on cover slips were briefly rinsed in PBS and the cells fixed for 10 min at room temperature in freshly prepared 1% paraformaldehyde in PBS. The fixed cells on cover slips were mounted on slides (Prolong Anti-Fade (Molecular Probes, Eugene, OR). Molecular clone from phage library generated from co-culture of GAB1 PBMC and SW480 cells (Huet et al., 1990; Peeters et al., 1989) SIV Images were collected using a Zeiss Confocal Laser Scanning Microscope, LSM-510 using an excitation wavelength of 488 nm with a LP-505 emission filter. Images were analyzed and 3-dimensional reconstructions of the subcellular localization of the VpuEGFP mutants were generated using LSM-510 software.
To examine the intracellular localization of the SIV cpz Vpu fusion proteins, co-transfection studies were performed using pDsRed2-ER, pECFP-Golgi and pECFP-Mem vectors (Clontech). 293 cells were co-transfected with vectors expressing one of the Vpu fusion proteins and either DsRed-ER, ECFP-Golgi or ECFP-Mem as described above. Cells expressing both proteins (i.e., the VpuEGFP and either ECFP protein or DsRed2-ER) were identified. Fluorescent digital images were obtained using a Zeiss LSM510 confocal microscope equipped with an Argon/2 laser (25 mW) for the excitation (488 nm, 50% laser power) and detection (band pass 505 -530 nm filter; BP505-530) for EGFP, excitation (458 nm, 100% laser power) and detection (band pass 475 -525 nm filter; BP475 -525) for ECFP, and excitation (558 nm, 100% laser power) and detection (band pass 588 nm filter: BP560) for DsRed2. Images were acquired in Multitrack channel mode (sequential excitation/emission) with LSM510 (v 3.2) software and a Plan-Apochromat 100X/1.4 Oil DIC objective with frame size of 2048 Â 2048 pixels. Detector gain was set initially to cover the full range of all the samples and background corrected by setting the amplifier gain, and all images were then collected under the same photomultiplier detector conditions and pinhole diameter.
Immunoprecipitation analyses
For radiolabeling studies, 293 cells were transfected as described above and at 48 h after transfection, the medium was removed and transfected cells were incubated in methionine/cysteine-free Dulbecco's modified Eagle's medium (DMEM) for 2 h. The cells were radiolabeled for 5 h with 500 ACi of 35 S-Translabel (methionine and cysteine, MP Biomedical, Costa Mesa, CA). EGFP containing proteins were immunoprecipitated from the cell lysates using an a-EGFP antibody and protein A Sepharose (PAS). Immunoprecipitates collected on PAS were washed three times, boiled in sample reducing buffer, and analyzed by SDS-PAGE (10% gel) (Pacyniak et al., 2005; Singh et al., 2003) . Proteins were then visualized by standard autoradiographic techniques.
Isolation of P100 and S100 fractions
For membrane enrichment studies, 293 cells were transfected with vectors expressing either pcEGFP, pcvpuEGFP or the SIV cpz Vpu fusion proteins. At 48 h, cells were washed three times with phosphate-buffered saline (PBS; pH 7.4) and then placed in a hypotonic solution consisting of 10 mM Tris -HCl, pH 7.4, 1 mM CaCl 2 and 1 mM MgCl 2 . The cells were disrupted by homogenization in a tight fitting Potter -Elevjhem homogenizer and nuclei removed by spinning at 1000 Â g for 10 min. The supernatant was removed and saved. The pellet (containing nuclei) was washed and pelleted an additional two times and the supernatants pooled. The supernatants were then subjected to centrifugation at 100,000 Â g (Beckman SW55Ti rotor, 32,000 rpm) for 30 min. The supernatant fraction and the pellet containing membranes were collected. The membrane enriched pellet was resuspended in 1Â RIPA buffer and the supernatant fraction made 1Â with respect to RIPA buffer. EGFP containing proteins were immunoprecipitated using an a-EGFP serum and (PAS) as described above. In other experiments, the P100 fraction was resuspended in phosphate-buffered saline (PBS, pH 7.4) containing 0.5% Triton X-100 and then centrifuged at 100,000 Â g for 30 min. The pellet and supernatant fractions were then subjected to immunoprecipitation analysis as described above using the a-EGFP serum.
Assays for CD4 surface expression and degradation

HeLa CD4
+ cells were grown on cover slips and transfected with pcvpuEGFP as described earlier. At 48 h post-transfection, cells were washed twice with wash buffer (PBS pH 7.2, containing 2% fetal calf serum and 0.01% NaN 3 ) and reacted with mouse anti-CD4 (clone SFCI12T4D11CD4, Beckman-Coulter, 1:50 dilution) for 45 min. After the incubation, cover slips were washed three times and incubated with rhodamine-conjugated secondary antibody (goat antimouse, Chemicon, 1:50 dilution) for 35 min followed by washing five times in buffer without serum. Cells were then fixed in 1% formalin for 10 min, washed twice, equilibrated with antifade buffer, and mounted on microscope glass slides using Anti-fade (Molecular Probes). Cells were immediately observed by laser scanning confocal microscopy using appropriate filters to visualize the EGFP containing proteins and visualization of CD4 staining. All the staining procedures were performed on ice and in the dark. HeLa CD4 + cells transfected with a vector expressing EGFP alone (pcEGFP) served as control for down-regulation of CD4 and cultures of HeLa CD4 + cells treated with wash buffer instead of primary antibody served as a negative control for CD4 staining. A minimum of 400 EGFP expressing cells were analyzed per construct.
In addition to detection of CD4 on the cell surface of transfected HeLa CD4 + cells, co-transfection experiments were performed using vectors expressing each VpuEGFP fusion protein and a vector expressing the human CD4 protein (pCMV4Neo; Goldsmith et al., 1995) . Cells were transfected with Vpu fusion and pCMV4Neo vectors at a 3:1 ratio to insure that all cells transfected with the CD4 expressing vector were also transfected with the vector expressing the Vpu fusion proteins. At 48 h post-transfection, cells were starved for methionine/cysteine and then radio-labeled with 500 ACi 35 S-methionine/cysteine for 1 h. The radiolabel was removed and replaced with medium containing cold excess methionine/cysteine for 5 h. In some experiments, cells were treated with the proteasome inhibitor MG132 (50 AM) during the radiolabeling and chase periods. Cells were lysed in RIPA buffer, lysates prepared, and the CD4 immunoprecipitated using a rabbit anti-CD4 (sc-7219; Santa Cruz Biotechnology) and PAS. Immunoprecipitates were collected, washed three times with 1Â RIPA and analyzed by SDS-PAGE (10% gel). Controls included co-transfection with pcEGFP (expressing on EGFP) as negative control and co-transfection with a pcvpuEGFP or pcvpu SC EGFP1 (expressing the subtype B and C Vpu) as a positive controls.
Site-directed mutagenesis of SIV cpz ANT and SIV cpz CAM13 vpu genes Site-directed mutagenesis was performed using complementary oligonucleotides (only sense oligonucleotide shown) and the Quick-Change Mutagenesis Kit (Stratagene) according to the manufacturer's instructions. Three sitedirected mutations were introduced into SIV cpz ANT vpu using oligonucleotide primers (sense strand shown) 5V-GCAATAGAAGAAAATGAGGAAGCCAAT-3V to change an aspartic acid residue at position 61 to an asparagine residue [Vpu ANT EGFP(D61N)]; oligonucleotide primer 5V-GCAA-TAGAAGAAAAGGAGGAAGCCAAT-3V to change the asparagine to a lysine residue [Vpu ANT EGFP(D61K)]; and oligonucleotide primer 5V-GAAGAAAAGGAGAAAGC-CAATACATAT-3V to change the glutamic acid at position 63 to a lysine [Vpu ANT EGFP(DE61,63KK)]. Similarly, oligonucleotide 5V-ATAGTGGAAATGAAGCCGATGGA-GGAGAGG-3V was used to change the serine residue at position 55 in the SIV cpz CAM13 vpu gene to an alanine residue [Vpu CAM13 EGFP(S55A)]. Sequence changes were confirmed by sequence analysis and the mutant vpu genes inserted into the pcDNA3.1(+) vector for expression studies.
